Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of Sciences (CAS) and comprising Beijing Digital Precision Medical Technology Co., Ltd, and Zhuhai Dipu Medical Technology Co., Ltd, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The round was led by Shanghai Daohe Healthcare Private Equity Fund, with participation from Hyfinity Investments and Rising Capital.
DPM, a leader in China’s molecular imaging space, enjoys backing from SBCVC and GREE, and has forged a strategic partnership with US healthcare giant Johnson & Johnson. The company’s impressive portfolio includes the world’s first optical 8CMOS 3D4K fluorescence endoscope camera system, registered and launched in December 2022, and the world’s first 8K fluorescence endoscope camera system, registered and launched in September 2023. DPM also offers a 4K fluorescence endoscope camera system and a white light endoscope camera system product matrix.- Flcube.com
